MAPK1 and fragile X syndrome: Furthermore, lovastatin reduced pERK levels in Nf1+/− and Ptpn11D61G/+ mice, and reduced pERK-dependent protein synthesis in the mouse model of Fragile X Syndrome, indicating its potency in restoring alterations of the RAS-ERK pathway10, 31, 47.